Background-Intravascular ultrasound (IVUS) is used to assess intermediate lesions in native coronary arteries; minimum lumen area (MLA) Ͻ4.0 mm 2 is accepted as a cutoff for a significant stenosis. We evaluated the IVUS in-stent MLA at 9-month follow-up that best predicted subsequent target lesion revascularization (TLR)-free survival in patients from the TAXUS IV, V, and VI studies. Methods and Results-In the combined TAXUS IV, V, and VI randomized trials, 9-month IVUS was available in 635 patients (331 treated with paclitaxel-eluting stents [PES] and 304 treated with bare-metal stents [BMS]) who did not require TLR in the first 9 months postintervention and who were followed for 3 years. The in-stent MLA that best predicted 3-year TLR-free survival was determined. At 9-months follow-up, IVUS-measured in-stent MLA was 5.7Ϯ2.3 mm 2 in the PES group and 4.8Ϯ2.3 mm 2 in the BMS group. Between 9 months and 3 years, TLR was required in 4.9% of patients who were treated with PES and 6.7% of patients who were treated with BMS. Multivariate analysis identified MLA at 9 months as a significant predictor of late TLR (hazard ratio, 0.63 [0.43-0.93]; Pϭ0.02). The ability of MLA to predict late TLR was further assessed using receiver operating characteristic analysis. MLA was found to be an acceptable discriminator for both PES (cϭ0.7448) and BMS (cϭ0.7329). Finally, the optimal thresholds of MLA that best predicted subsequent TLR-free survival were determined to be 4.2 mm 2 for PES and 4.0 mm 2 for BMS. Conclusion-In the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months had a high subsequent TLR-free survival rate whether treated with PES or BMS. MLA measured by IVUS at 9 months predicted subsequent TLR with a cutoff similar to intermediate, 
randomized TAXUS IV, V, and VI trials. 8 -10 These trials included substudies of patients who underwent 9-month follow-up IVUS imaging and 3-year clinical follow-up. We hypothesized that 9-month IVUS can predict 3-year target lesion revascularization (TLR)-free survival in patients receiving PES and BMS.
Methods

Patient Population and Protocol
TAXUS IV, TAXUS V, and TAXUS VI were prospective, double-blind, BMS-controlled trials in which patients with a single de novo native coronary artery lesion were randomly assigned to treatment with a PES or an otherwise identical BMS (Boston Scientific, Natick, Mass). 8 -10 The TAXUS IV and V studies used the TAXUS slow-release formulation (commercially available), whereas TAXUS VI used the TAXUS moderaterelease formulation (not commercially available). IVUS substudy data from these trials were analyzed at a single core laboratory (Medlantic Research Institute, Washington Hospital Center, Washington, DC) as described previously. 11 Of the 2918 patients enrolled in the 3 trials, the first 956 patients enrolled at prespecified IVUS substudy sites underwent serial volumetric IVUS analysis and were included in the IVUS cohort, including 268 from TAXUS IV, 509 from TAXUS V, and 179 from TAXUS VI. In the IVUS cohort, 635 patients (331 PES and 304 BMS) did not require TLR in the first 9 months post-stent implantation, including the day of the 9-month angiography/IVUS follow-up and were followed for 3 years.
TLR was defined as any ischemia-driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. All TLR throughout follow-up (up to and including the 3-year follow-up) were adjudicated by the Clinical Events Committee (Harvard Clinical Research Institute, Boston, Mass). If the lesion diameter stenosis was Ն70%, no additional clinical evidence of ischemia was needed. If the lesion diameter stenosis was Ն50% but Ͻ70%, one of the following pieces of evidence was needed: (1) positive functional study corresponding to the area served by the target lesion, (2) ischemic ECG changes at rest in a distribution consistent with the target vessel, or (3) ischemic symptoms referable to the target lesion. If the lesion diameter stenosis was Ͻ50%, a markedly positive functional study or ECG changes corresponding to the area served by the target vessel was needed.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agreed to the manuscript as written.
Angiography Analysis
Two or more angiographic projections of the stenosis after intracoronary nitroglycerin were acquired with repetition of identical angiographic projections of the lesion at the time of follow-up angiography. With the contrast-filled catheter as the calibration source, quantitative angiographic analysis was performed using a validated automated edge-detection algorithm (MEDIS Medical Imaging System, Maastricht, The Netherlands) by a technician who was unaware of the clinical or IVUS findings and who was blinded to the treatment arm.
IVUS Protocol and Analysis
Clinical sites were selected based on their IVUS experience and volume. Volumetric IVUS was performed immediately after stent implantation and at 9-month follow-up in patients at the IVUS substudy sites of each trial until the prespecified enrollment numbers in each trial were obtained. IVUS imaging was performed after intracoronary administration of 0.1 to 0.2 mg of nitroglycerin using motorized transducer pullback (0.5 mm/s) and contemporary, commercial scanners. Images were continuously recorded throughout the stent, including Ͼ5-mm segments distal and proximal to the stent. Images were recorded onto s-VHS videotape, compact discs, or magneto-optical discs for offline analysis at a single, independent core laboratory by a technician who was unaware of treatment assignment or patient clinical outcomes. With the use of computerized planimetry (TapeMeasure, Indec Systems, Mountain View, Calif.), stent and lumen borders were manually traced, and stent, lumen, and intimal hyperplasia (stent-lumen) areas were calculated every 1 mm within the stented segment. Volumes were calculated using the Simpson rule. Percentage of intimal hyperplasia (%IH) was defined as intimal hyperplasia volume divided by stent volume. MLA was defined as the smallest lumen area within the length of the stent. Minimum stent area was defined as the smallest stent area within the length of the stent.
Statistical Analysis
Categorical variables were summarized as frequencies and percentages and were compared between groups using 2 tests or Fisher exact tests, as appropriate. Continuous variables were presented as meanϮSD and compared between groups using 2-tailed, unpaired t tests;if parameters were not normally distributed per KolmogorovSmirnov test, then the Wilcoxon 2-sample test was used. Multivariate analysis was used to determine predictors of late TLR (between 9 months and 3 years). All covariates were modeled univariately for each outcome and multivariately using a stepwise procedure in the Cox regression model. Baseline patient and lesion characteristics and 9-month IVUS variables were included. Statistical significance was set at PϽ0.05. For each outcome, predictors were listed in ascending order of probability value. Coefficients with probability values Ͼ0.05 were not listed.
Receiver operating characteristic (ROC) analysis was used to measure the ability of MLA and %IH at 9-months follow-up to discriminate between those subjects who experienced TLR within the subsequent follow-up (between 9 months and 3 years) compared with those who did not. The ROC curves plot the probability of detecting true signals (sensitivity) against false signals (1 Ϫ specificity) over an entire range of possible cut points. Acceptable discrimination is considered if the c statistic is Ն0.7 but Ͻ0.8; excellent and outstanding discrimination are considered for c statistics Ն0.8 but Ͻ0.9, and Ն0.9, respectively. To determine the optimal IVUS cutoff value for each treatment group to best predict late (3-year) TLR, the cross point of sensitivity and specificity curves was used.
The Kaplan-Meier product-limit method and log-rank tests were used to assess time-to-event end points between treatment groups. Differences were considered to be statistically significant when the probability value was Ͻ0.05.
Results
This study consisted of 635 patients with IVUS data (331 PES and 304 BMS) who did not require TLR in the first 9 months post-stent implantation, who were not staged for intervention after the 9-month coronary angiography and IVUS, and who were subsequently followed for 3 years. Between the 9-month and 3-year follow-up visits, TLR was necessary in 16 patients who were treated with PES (4.9%) and 20 patients who were treated with BMS (6.7%). The time from 9-month follow-up IVUS to the late TLR event was 291Ϯ282 days in the PES group and 156Ϯ210 days in the BMS group. TLR-free survival curves are shown in Figure 1 and were not different between the 2 groups. Only 1 patient in each group developed stent thrombosis between 9 months and 3 years.
Patients and Lesion Characteristics
Baseline clinical and lesion characteristics of late-TLR patients were similar to those of TLR-free patients in the PES and BMS groups (Tables 1 and 2 ). In addition, baseline clinical and lesion characteristics were similar between the PES and BMS groups (Tables 1 and 2 ). Thus, baseline clinical characteristics, including incidence of diabetes mellitus and lesion severity, did not affect the magnitude of late TLR.
IVUS Findings at 9 Months in the PES Group
At 9 months, patients treated with PES who required revascularization within 3 years had a smaller minimum stent area (5.4Ϯ0. 4 (Table 3) . Figure 2 ). In addition, ROC analysis of %IH volume Figure 1 . Kaplan-Meyer TLR-free survival curves in 635 patients (331 treated with PES and 304 treated with BMS) who did not require TLR in the first 9 months post-stent implantation and who were followed for 3 years. At 3 years, TLR-free survival rates in the PES-and BMS-treated groups were 95.1% and 93.3%, respectively. showed that the c statistics in TAXUS and BMS groups were 0.7019 and 0.8036, respectively (Figure 3 ). Using the cross points of the sensitivity and specificity curves for 9-month MLA and %IH as discriminators for 3-year TLR probability, the best cutoff values were 4.2 mm 2 (PES) and 4.0 mm 2 (BMS) for MLA ( Figure 4 ) and 24.5% (PES) and 23.9% (BMS) for %IH volume. The rate of late TLR in PES-treated patients with a 9-month MLA Ն4.0 mm 2 was 2.9% as compared with 11.6% in patients with an MLA Ͻ4.0 mm 2 (Pϭ0.0013). Although 9-month MLA Ն4.0 mm 2 demonstrated a high predictive value for TLR-free survival of 97.2%, MLA Ͻ4.0 mm 2 had only an 11.4% predictive value of late TLR. In the BMS cohort, the late-TLR rate in patients with 9-month MLA Ն4.0 mm 2 was 3.5% as compared with 11.1% in patients with MLA Ͻ4.0 mm 2 (Pϭ0.0090). Similar to PES, the predictive value of an MLA Ն4.0 mm 2 for TLR-free survival in BMS patients was 96.6%, whereas the predictive value of MLA Ͻ4.0 mm 2 for late TLR was only 10.9%.
IVUS Findings at 9 Months in the BMS Group
Discussion
The major findings of this study were as follows: (1) in the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months Several studies have reported a strong correlation between anatomic data obtained from IVUS and physiological data obtained using coronary flow reserve, FFR, or radionuclide angiographic stress testing. Abizaid et al 5 studied 112 de novo lesions in 86 patients with both IVUS and coronary flow reserve; an IVUS lumen cross-sectional area of 4.0 mm 2 predicted a coronary flow reserve of 2.0 with a diagnostic accuracy of 89%. Nishioka et al 12 reported that an IVUS MLA Ͻ4.0 mm 2 correlated with abnormal stress myocardial single-photon emission computed tomography (sensitivity of 88% and specificity of 90%). Takagi et al 13 14 studied 357 intermediate lesions in 300 patients in whom intervention was deferred based on IVUS findings; TLR was required in 6% of the patients at a mean follow-up of 13 months. Moreover, patients with an MLA Ն4.0 mm 2 by IVUS had only a 2.8% rate of TLR, although the TLR rate was higher in diabetics as compared with nondiabetics.
There have been preliminary reports on the use of IVUS to assess intermediate ISR lesions. Nishioka et al 15 studied 150 intermediate ISR lesions in 142 patients. Repeat intervention was deferred if the MLA measured by IVUS was Ͼ3.5 mm 2 ; in these patients, the 2-year event-free survival rate was high (96.5%). Lee et al 16 evaluated the long-term clinical outcome of asymptomatic patients with moderate ISR after repeat intervention was deferred; during a mean follow-up of 26 months, TLR (3% and 2%, respectively) and major adverse cardiac event--free survival (87% and 85%, respectively) were similar to a group of patients without ISR. As in the study by Abizaid et al 14 of native artery lesions, the presence of diabetes mellitus influenced late events in ISR lesions. 16 However, because of the small number of patients who required 3-year TLR in the current study, we were unable to assess the impact of diabetes mellitus (or other risk factors) on long-term outcome. Intracoronary physiology has also been used to assess ISR lesions. Compared with reversible perfusion defects on myocardial scintigraphy, an FFR Ͻ0.75 predicted hemodynamically significant ISR with a sensitivity of 92%. Krüger et al 17 studied 42 intermediate ISR lesions. In 22 patients with an FFR Ͼ0.75, there were no adverse coronary events related to the stented lesion in the subsequent 6 months. Thus, similar to IVUS, the FFR threshold for a significant ISR lesion was similar to de novo lesions.
Kimura et al 18 demonstrated that in-stent luminal diameter measured by quantitative angiography in patients treated with the Palmaz-Schatz stent improved from 1.95 to 2.09 mm between 6 months and 3 years postimplantation. In a subsequent report, Kimura et al 19 analyzed late clinical and angiographic outcomes after Palmaz-Schatz stent implantation. Among the 405 patients in this second study, quantitative angiographic analysis of 179 lesions in 173 patients showed a minimum lumen diameter of 2.62 mm postprocedure, 2.00 mm at 6 months, 2.19 mm at 3 years, and 1.85 mm beyond 4 years. These data indicated a triphasic BMS luminal response, characterized by early restenosis, intermediate-term neointima regression (from 6 months to 3 years), and late renarrowing (beyond 4 years).
In support of intermediate-term neointima regression after BMS implantation, Kuroda et al 20 reported that intimal hyperplasia area measured by IVUS decreased from 3.0 mm 2 at 6 months to 2.2 mm 2 at 12 months. Also using IVUS, Hong et al 21 showed that there was intimal hyperplasia regression in most BMS-treated lesions (76%), with an overall mean decrease in intimal hyperplasia area from 2.6 mm 2 at 6 months to 2.3 mm 2 at 2 years. The longest available IVUS follow-up after PES implantation is also 2 years. In an IVUS substudy from TAXUS II, Aoki et al 22 showed that there was a modest increase in %IH in the PES group as compared with a decreased in %IH in the BMS group between 6 months and 2 years. In another long-term IVUS substudy from ASPECT (a study that used a nonpolymeric paclitaxel stent), Park et al 23 demonstrated a "late catch-up" of intimal hyperplasia growth from 6 to 18 months, especially in the high-dose group. These differences between PES and BMS led to the hypothesis that the 9-month MLA cutoff predicting late TLR would be larger in PES as compared with BMS because a larger MLA would be necessary to accommodate ongoing neointimal hyperplasia in PES-treated lesions. In fact, this was not the case; the MLA cutoffs were nearly identical. This finding, along with virtually identical event-free survival curves, also suggested that any late intimal hyperplasia would have little clinical consequence. 
Study Limitations
First, in this study, we evaluated only PES; however, the late intimal hyperplasia growth patterns in other drug-eluting stents might be similar to those in PES. Second, the results in this study are limited to vessel diameters, stent lengths, and lesion complexities in the TAXUS IV, V, and VI trials. Third, the TAXUS trials were not undertaken to evaluate the efficacy of IVUS for decision-making in intermediate ISR lesions. Since an MLA Ͻ4.0 mm 2 had low predictive value for late TLR, and given the lack of evidence that treatment of these lesions would benefit patients without objective evidence of ischemia, these findings should not be taken as a prescription to routinely treat patients with MLA Ͻ4.0 mm 2 . Fourth, comparisons between groups are not powered and are used either for descriptive purpose or to show consistency with the predictive analysis, which is the major focus of this article. Finally, these results are based on IVUS analysis only and cannot be extrapolated to any angiographic data because of lack of correlation between angiographic and IVUS measures.
Conclusions and Clinical Implications
In the combined IVUS analysis of TAXUS IV, V, and VI, patients who did not require TLR within the first 9 months had a low subsequent (3-year) TLR rate whether treated with PES or BMS. In-stent MLA measured by IVUS at 9 months predicted subsequent 3-year TLR-free survival in both the PES and BMS groups, with cutoffs virtually identical to and event rates as low as in intermediate, de novo, native artery lesions. The low late-TLR rates in patients with MLA Ն4 mm 2 at 9 months brings uncertainty to the practice of intervening on moderate lesions at routine follow-up, even in the absence of symptoms mostly due to the oculostenotic reflex. Conversely, patients with intermediate ISR lesions (MLA Ն4.0 mm 2 ) can be treated medically with good long-term outcomes. Thus, IVUS may also be a useful modality for decision-making in intermediate ISR lesions.
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